Sorrento Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sorrento Therapeutics, Inc.
US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
Location, Location, Location: Will Sorrento’s China-Only NSCLC Data Fly With US FDA?
Sorrento plans to meet with the US FDA regarding abivertinib, but the agency’s tough stance on drug approvals based on single-country studies could thwart the company’s efforts.
- Medical Devices
- Specialty Pharmaceuticals
- Site Specific
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Large Molecule
- Other Names / Subsidiaries
- ADNAB, Inc.
- Levena (Suzhou) Biopharma Co., Ltd
- SCILEX Pharmaceuticals, Inc.
- Scilex Holding Company
- Scintilla Pharmaceuticals, Inc.
- Semnur Pharmaceuticals, Inc.
- Sherrington Pharmaceuticals
- SmartPharm Therapeutics, Inc.
- TNK Therapeutics, Inc.
- Virttu Biologics Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.